Stock Appreciation Rights (Details) (Stock Appreciation Rights (SARs) [Member], USD $)	3 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jun. 17, 2013
SARS Valuation Assumptions [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		320,000	360,000
Stock Appreciation Rights, Weighted Average Grant Price		$ 0.418	$ 0.409
Stock Appreciation Rights, Weighted Average Contractual Life Remaining		5.61	5.17
Stock Appreciation Rights, Weighted Average Market Price	$ 0.768	$ 0.270
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	140.65%	143.73%
Weighted Average Expected Life		4.84	4.52
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.17%	0.69%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Stock Appreciation Rights, Weighted Average Fair Value Price	$ 0.731	$ 0.389
Weighted Average Aggregate Fair Value	$ 181,000	$ 57,000
Weighted Average Aggregate Intrinsic Value	99,000	2,400
Stock Appreciation Rights, Compensation Expense	93,000	6,800
Unrecognized Compensation Expense Related to Non-Vested SARS Granted	50,000	18,000
Expected Period to Recognize Compensation Expense Related to Non-Vested SARSs Granted		2.28	2.13
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent		$ 59,000	$ 189,000
Maximum [Member]
SARS Valuation Assumptions [Line Items]
Stock Appreciation Rights, Upper Range of Grant Price		$ 0.695	$ 0.695
Minimum [Member]
SARS Valuation Assumptions [Line Items]
Stock Appreciation Rights, Lower Range of Grant Price		$ 0.208	$ 0.208